Drug Discovery
Novalaunch: A better start
Senior biologists, medicinal and computational chemists with big pharma experience support discovery projects across all platforms, putting early-stage biotech firms on a firmer path.
Chemistry
Our expert chemists thoughtfully apply our resources — including a proprietary DNA-encoded library — to refine and optimize the compound, perfecting the profile no matter how time-sensitive or complex the challenge.
Biophysics
See more clearly with our comprehensive biophysics platform. You will get a more meaningful, complete view of the molecule and interactions: characterization, appearance, behavior, binding.
Pharmacology and DMPK
Move closer to market with our therapeutic area expertise, in vitro assays, in vivo models and deep understanding of both disease and drug mode of action. Our custom solutions help connect preclinical efficacy with clinical success.
ADME-PK and preformulation
A rigorous suite of assays to test compound profile: in vitro ADME assays, in vivo PharmacoKinetics, as well as bioanalysis services, formulation design and batch characterization.
Medicinal chemistry
Interdisciplinary team focused on the design, synthesis, improvement of biological activity, and the safety and pharmacokinetic properties in order to discover new drug candidates.
Cheminformatics
Cheminformatics is a powerful field utilizing computational chemistry and computer modeling to explore molecular behavior and predict the properties of new compounds. By employing various cheminformatics services and computational drug discovery techniques, our researchers can significantly accelerate a medicinal chemistry project and reduce timelines, making our cheminformatics CRO solutions ideal for modern pharmaceutical R&D.
DNA-Encoded Libraries
DNA-encoded libraries (DELs) represent a robust approach to hit identification and rapid lead generation. However, for too long, DNA-encoded library screening has been viewed primarily as a “number game”. Our DEL services deliver a different approach with a fully integrated DNA-encoded library CRO platform, designed to maximize hit quality and accelerate discovery timelines. The approach combines advanced library design, rigorous quality control, AI-driven DEL data analysis, and drug-like confirmed hits, supporting pharma-proven results for challenging targets.
Therapeutic areas
Sabine Gratzer
Distinguished research fellow
30 years’ experience. Pharmacology GPCR expertise. Metabolism. CNS. Immuno-oncology.
Lionel Trottet
Director DMPK Pharmacokinetics and ADME
More than 25 years of experience in drug discovery. DMPK representative in drug discovery projects in big pharma and biotech (GSK, Galapagos).
Ruel Cedeno
Head of cheminformatics
Cheminformatics, AI, machine learning, and computational drug design. Eiffel Excellence Award and AMU Thesis Prize.
